Mitsubishi Tanabe Pharma, Novartis preclinical data

Researchers at the ALS Therapy Development Institute reported data from a mouse model of ALS showing that Gilenya significantly and dose-dependently reduced circulating levels of CD4 and CD8 lymphocytes from baseline to day 100 vs. placebo. Gilenya also slowed body weight loss, slowed disease progression or paralysis and improved survival vs. placebo. The not-for-profit institute, which refers to Gilenya as TDI 132, plans to start a Phase II trial of the product to treat ALS in 2H12. ...